C反应蛋白在慢性阻塞性肺疾病急性加重期意义及治疗研究.docVIP

C反应蛋白在慢性阻塞性肺疾病急性加重期意义及治疗研究[摘要] 目的 探讨C反应蛋白(CRP)在慢性阻塞性肺疾病急性加重期的临床意义及痰热清注射液治疗前后CRP的变化。方法 比较80例慢性阻塞性肺疾病患者急性加重期及稳定期的CRP和WBC总数的变化。并随机分为给予基础治疗的对照组40例和加用痰热清注射液治疗的治疗组40例,比较治疗前后两组CRP的变化。结果 AECOPD患者 CRP水平显著高于稳定期患者(P0.05),治疗后对照组CRP水平显著高于痰热清治疗组(P0.05)。结论 CRP可作为慢性阻塞性肺疾病急性加重期的预测因子,痰热清注射液抗炎的作用明显,可用于慢性阻塞性肺疾病急性加重期的治疗。 [关键词] C反应蛋白;慢性阻塞性肺疾病急性加重期;痰热清 [中图分类号] R541.5 [中图分类号] A[文章编号] 1673-9701(2009)24-93-02 Clinical Value of C-reactive Protein in Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Treatment Analysis YIN ShiqiBAI LeQIAN Yueqing Department of Respiratory,Electric Power Hospital of Heilongjiang Province,Harbin 150030,China [Abstract] Objective To discuss the clinical significance of C-reactive protein (CRP)in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and the changes of CRP before and after treatment with Tanreqing injection. Methods CRP and WBC were compared in the acute exacerbation and the stable stage of 80 cases of COPD which were randomly divided into control group of 40 cases given foundation treatment and treatment group of 40 cases given Tanreqing injection besides foundation treatment. CRP change was compared before and after treatment. Results The CRP level in AECOPD was significantly higher than that in stable COPD(P0.05). The CRP level in the control group was higher than that in the treatment group(P0.05). Conclusion CRP is a predictor of AECOPD. The anti-inflammation function of Tanreqing is obvious andTanreqing injection is available in treatment of AECOPD. [Key Words] CRP;Acute exacerbation of chronic obstructive pulmonary disease;Tanreqing 慢性阻塞性肺疾病在全世界范围内都有很高的发病率和死亡率。急性加重的反复发作是慢性阻塞性肺疾病病程中的重要特征。而细菌感染造成的炎症反应是急性加重的根本原因。C反应蛋白(CRP)是一种由肝细胞合成的能与肺炎双球菌多醣体反应的急性时相蛋白,在微生物感染或组织炎症时,6~9h后即可升高,因此常作为反映机体炎症的指标。近年来,由于仪器设备的改进和高灵敏度检测方法的建立,CRP的临床意义被重新评估[1]。本文对我院收治的80例COPD急性加重期患者的CRP检测资料进行分析,探讨CRP与AECOPD的关系及痰热清治疗的效果,现报道如下。 1对象与方法 1.1病例来源 COPD急性加重期病人80例,均为2007年10月～2008年10月收入我科的住院患者。诊断均符合我国《慢性阻塞性肺病诊治指南》制定的诊断标准[2]